Lab
Pcr-Dx of Colorado, LLC
Pcr-Dx of Colorado, LLC was paid $762K by Medicaid between Sep 2021 and Dec 2024, across 20 billing codes. Its largest line is 87798, Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism — 30% of everything it billed.
33Billing provider infoPCR-DX OF COLORADO, LLC
FORT COLLINS, CO 80526
FORT COLLINS, CO 80526
33aNPI1467023499assigned 07/09/2021
33bProvider typeClinical Medical Laboratory
28Total paid$762K
24GClaims12,496
24DCodes billed20
24AFirst – last monthSep 2021 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Colorado
Rank by total paid#26 of 91
Median peer was paid$53K
This provider vs. median14×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 1,136 | $45K | |
| 2022 | 7,739 | $537K | |
| 2023 | 1,800 | $148K | |
| 2024incomplete | 1,821 | $33K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 30% | 1,477 | 1,322 | $228K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 20% | 432 | 387 | $156K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 18% | 2,157 | 1,849 | $141K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 6.0% | 2,167 | 1,850 | $46K |
| 87631 | 4.8% | 272 | 262 | $37K | |
| 87500 | 4.1% | 1,287 | 1,117 | $31K | |
| 87640 | 2.8% | 906 | 818 | $21K | |
| 87581 | 2.6% | 642 | 599 | $20K | |
| 87486 | 2.6% | 630 | 587 | $20K | |
| 87481 | 2.2% | 341 | 321 | $17K | |
| 87653 | 2.2% | 770 | 704 | $17K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 578 | 538 | $7K |
8 more codes
| 87529 | <1% | 87 | $5K | |
| 87641 | <1% | 360 | $5K | |
| 87511 | <1% | 111 | $4K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 87 | $3K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 89 | $3K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 70 | $2K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 15 | $1K |
| 87563 | <1% | 18 | $561.44 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLILLY, ROB (CFO)